Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Treating advanced kidney cancer—miles to go before we sleep

Nature Reviews Clinical Oncology volume 10, pages 614–615 (2013)Cite this article

Subjects

A randomized phase III trial comparing pazopanib with sunitinib in patients with advanced clear cell renal cell carcinoma showed that although progression-free survival and overall survival were similar, pazopanib was better tolerated. Recent advances in genomics and metabolomics have provided novel insights that could be leveraged to improve therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722–731 (2013).

    Article  CAS  Google Scholar 

  2. Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860–867 (2013).

    Article  CAS  Google Scholar 

  3. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360–363 (2010).

    Article  CAS  Google Scholar 

  4. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).

    Article  CAS  Google Scholar 

  5. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

  6. Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19, 3259–3267 (2013).

    Article  CAS  Google Scholar 

  7. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277–285 (2010).

    Article  CAS  Google Scholar 

  8. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2011).

    Article  Google Scholar 

  9. Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385–388 (2011).

    Article  Google Scholar 

  10. Linehan, W. M. et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 61, 329–343 (2010).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The authors thank Christopher Rickets for critical reading of the manuscript and acknowledge the outstanding editorial and graphics support by Georgia Shaw.

Author information

Authors and Affiliations

  1. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC Room 1W-5940, Bethesda, 20892, MD, USA

    W. Marston Linehan & Ramaprasad Srinivasan

Authors
  1. W. Marston Linehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramaprasad Srinivasan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Marston Linehan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linehan, W., Srinivasan, R. Treating advanced kidney cancer—miles to go before we sleep. Nat Rev Clin Oncol 10, 614–615 (2013). https://doi.org/10.1038/nrclinonc.2013.183

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.183

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing